Skip to content

L · 0ELV.L · DRUG MANUFACTURERS - SPECIALTY & GENERIC

Guerbet S.A. (0ELV.L) intrinsic value and stock valuation

$6.60as of 2026-11-21 · Mkt cap 132.79M

Data updated · price as of 2026-11-21

IC valuationIntrinsic value, upside vs price and the fair-value band are available to Pro members.
P/E
Pro
P/B
Pro
P/S
Pro

Price history

Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.

Guerbet S.A. DCF and intrinsic value

InvestorsCraft values 0ELV.L with the Chepakovich two-stage DCF model. How the model works · Run your own DCF prefilled from 0ELV.L’s statements →

Guerbet S.A. Graham Number

The Graham Number is not defined for negative earnings or book value. Guide · Calculator →

Healthcare · Drug Manufacturers - Specialty & Generic Villepinte 93420 guerbet.com

How the business is doing

Fiscal 2012–2025, USD

Revenue
$786.4M+2% 5y CAGRd
20122025
Net income
-$-108.33M
20122025
Free cash flow
$31.4M-10.9% 5y CAGRd
20122025
Total equity
$260.1M-6.7% 5y CAGRd
20122025

Is it expensive?

Each multiple against its own 15-year range, or against peers where no history is available

P/E
Pro
with Pro
P/B
Pro
with Pro
P/S
Pro
with Pro
EV/EBITDA
Pro
with Pro
P/EG
Pro
with Pro
P/TBV
Pro
with Pro

Financials

Statements by fiscal year

Fiscal 2012–2025, USD
20252024202320222021
Revenue$786.4M$841.1M$795.7M$753.3M$732.1M
Operating income$1.36M$42.8M$38.7M$30.5M$36.8M
Net income-$-108.33M$16.1M$23.9M-$-41.12M$32.6M
EPSd-$-8.6M$1.28M$1.9M-$-3.26M$2.58M
Operating cash flow$61.3M$60.7M$27.4M$25.9M$110.7M
Capital expenditure-$-29.86M-$-32.05M-$-41.55M-$-50.52M-$-48.93M
Free cash flow$31.4M$28.7M-$-14.12M-$-24.63M$61.8M
Total assets$930M$1.04B$1.03B$939.6M$1B
Total debt$437.8M$400.9M$387.1M$312M$333.5M
Net debt$322.3M$350.7M$335.8M$270.4M$217.8M
Total equity$260.1M$391.6M$378.3M$379.6M$405.1M
Cash and short-term investments$115.5M$50.2M$51.3M$41.7M$115.7M
Income statement
20252024202320222021
Revenue$786.4M$841.1M$795.7M$753.3M$732.1M
Cost of revenue$602.4M$620.1M$206.2M$564.2M$556.4M
Gross profit$184M$221M$589.5M$189.1M$175.7M
Research and development expenses$0.00$76.2M$81.2M$70M$65M
Selling, general and administrative expenses$0.00$84.1M$471M$80.3M$53.8M
Other expenses$182.7M$17.9M-$-1.38M$8.36M$20.1M
Operating expenses$182.7M$178.2M$550.8M$158.7M$138.9M
Cost and expenses$785.1M-$-798.27M$757M$722.8M$695.3M
Interest income$370K$280K$120K$30K$60K
Interest expense$19.8M$20.5M$10.6M$4.57M$5.34M
Depreciation and amortization$60.9M$61.3M$50.9M$60.8M$56M
Ebitda$62.2M$96.7M$90.1M$32.3M$85.1M
Operating income$1.36M$42.8M$38.7M$30.5M$36.8M
Total other income/expenses, net-$-115.03M$0.00-$-7.86M-$-63.53M-$-12.98M
Income before tax-$-113.67M$14.9M$30.8M-$-33.08M$23.8M
Income tax expense-$-1.01M$1.43M$8.64M$8.03M-$-8.83M
Net income-$-108.33M$16.1M$23.9M-$-41.12M$32.6M
Weighted average shares outstanding$12.6M$12.6M$12.6M$12.6M$12.6M
Weighted average diluted shares outstanding$12.6M$12.6M$12.6M$12.6M$12.6M
Balance sheet
20252024202320222021
Cash and short-term investments$115.5M$50.2M$51.3M$41.7M$115.7M
Net receivables$173.7M$209.1M$149.6M$162.4M$161.7M
Inventory$296.4M$305.7M$305.2M$276.4M$203.8M
Total current assets$600.7M$590M$581.6M$509.7M$495.5M
Property, plant and equipment, net$214.7M$291.3M$293.9M$286.1M$274.1M
Goodwill and intangible assets$61.5M$106.7M$97.1M$97.9M$188.6M
Long-term investments$18.8M$13.3M$12.9M$20.2M$12.8M
Total non-current assets$329.4M$447.3M$443.6M$430M$505.4M
Total assets$930M$1.04B$1.03B$939.6M$1B
Accounts payable$85.3M$95.1M$92.9M$103.7M$81M
Short-term debt$45.7M$50.3M$13M$33.6M$33.9M
Deferred revenue$0.00$0.00$29.6M$19.4M$15M
Total current liabilities$241.2M$254.5M$229.2M$239.6M$236.9M
Long-term debt$392.1M$350.6M$374.1M$278.4M$299.7M
Deferred revenue, non-current$0.00$0.00$13.5M$13.4M$11.2M
Total non-current liabilities$428.7M$391.2M$417.7M$320.5M$358.9M
Capital lease obligations$10.5M$21.4M$22.5M$21.7M$19M
Total liabilities$669.9M$645.7M$647M$560.1M$595.7M
Common stock$12.6M$12.6M$12.6M$12.6M$12.6M
Retained earnings-$-44.05M$52.5M$23.9M$66.7M$132.8M
Accumulated other comprehensive income (loss)$286.6M$317.4M$341.8M$288.5M$247.9M
Total equity$260.1M$391.6M$378.3M$379.6M$405.1M
Total investments$18.8M$13.3M$12.9M$20.2M$12.8M
Total debt$437.8M$400.9M$387.1M$312M$333.5M
Net debt$322.3M$350.7M$335.8M$270.4M$217.8M
Cash flow statement
20252024202320222021
Net income-$-108.33M$16.1M$23.9M-$-41.12M$32.6M
Depreciation and amortization$60.9M$61.3M$61.2M$60.8M$56M
Stock-based compensation$0.00$0.00$200K-$-400K$610K
Change in working capital$5.18M-$-12.25M-$-64.45M-$-58.38M$13.1M
Accounts receivable$27.3M-$-27.35M-$-28.97M-$-1.56M-$-6.64M
Inventory-$-18.58M-$-6.57M-$-36.27M-$-68.23M$4.58M
Accounts payable-$-7.04M$1.89M-$-10.34M$22.2M$16M
Net cash provided by operating activities$61.3M$60.7M$16.8M$25.9M$110.7M
Investments in property, plant and equipment-$-36.61M-$-56.99M-$-41.55M-$-50.52M-$-48.93M
Acquisitions, net$560K$1.24M-$-1.95M$1.19M$840K
Net cash used for investing activities-$-33.76M-$-53.16M-$-59.93M-$-55.4M-$-52.24M
Common stock issued$0.00$0.00$0.00$0.00$590K
Common stock repurchased$0.00$0.00$0.00$0.00$0.00
Dividends paid$0.00-$-6.3M-$-6.31M-$-10.73M-$-8.81M
Net cash used for financing activities$40.1M-$-7.07M$55.4M-$-43.99M-$-36.03M
Net change in cash$65.3M-$-1.04M$9.6M-$-74.05M$19M
Cash at end of period$115.5M$50.2M$51M$41.7M$115.7M
Operating cash flow$61.3M$60.7M$27.4M$25.9M$110.7M
Capital expenditure-$-29.86M-$-32.05M-$-41.55M-$-50.52M-$-48.93M
Free cash flow$31.4M$28.7M-$-14.12M-$-24.63M$61.8M
USD millions

Line items

    USD millions

    Line items

      USD millions

      Line items

        About Guerbet S.A.

        Guerbet SA engages in the development and marketing of contrast media products, delivery systems, medical devices, and related solutions. The company offers Optiray and Xenetix, which are non-ionic monomeric and iodinated contrast agents; Telebrix Gastro, a meglumine ioxitalamate solution; Conray, an iothalamate meglumine injection; Micropaque/Microtrast, a diagnostic imaging interconnected solution; Dotarem, a gadoteric acid-gadoterate meglumine, and Artirem, a gadoteric acid that acts as a contrast agent for MRI, as well as prefilled syringes, injectors, accessories, and consumables for MRI, CT, and Cath Lab. It also provides digital solutions, such as Contrast&Care, an injection management solution; Dose&Care, an X-ray dose management solution; and icobrain, a cloud-based AI solution to quantify disease-specific brain structures for acute and chronic neurological conditions on MR and CT, as well as OptiProtect services. In addition, the company provides products for interventional radiology, including Lipiodol ethyl esters of iodinated fatty acids of poppyseed oil; Vectorio, a mixing and injection system for conventional trans-arterial chemoembolization; Patent Blue V, a blue dye; Axessio, a peripheral micro guidewire; and SeQure and DraKon, which are microcatheters. Further, it offers Hydra Vision, a digital imaging system for urological, gastroenterological, and gynecological treatment, as well as planning and diagnostic procedures; and urology accessories and consumables. The company was founded in 1926 and is headquartered in Villepinte, France.

        CEO
        Philippe Bourrinet
        Employees
        2.78K
        Beta
        0.99

        Explore

        Frequently asked questions

        What is the intrinsic value of Guerbet S.A. (0ELV.L)?

        InvestorsCraft does not currently publish an intrinsic value for 0ELV.L. How the IC value is calculated.

        Is 0ELV.L undervalued?

        InvestorsCraft does not publish an undervaluation signal for 0ELV.L at this time.

        How is the intrinsic value calculated?

        InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.

        How often is this page updated?

        Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.

        Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.